Adalimumab in Adult Japanese Subjects With Psoriasis
Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Psoriasis
Intervention: adalimumab (Biological); adalimumab (Biological)
Phase: Phase 2/Phase 3
Status: Active, not recruiting
Sponsored by: Abbott
Official(s) and/or principal investigator(s):
Noritaka Inomata, Ph.D., Study Director, Affiliation: Abbott
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with
Official title: A Multicenter Open-Label Continuation Study of the Long-Term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study design: Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Primary outcome: PASI 50 Response
Incidence of AEs
Minimum age: 20 Years.
Maximum age: N/A.
- Subjects who completed study M04-688
- Subject is considered by the investigator, for any reason, to be an unsuitable
candidate for the study
Locations and Contacts
Starting date: April 2006
Last updated: March 27, 2008